ID   CWR-R1-EnzR
AC   CVCL_RA55
DR   cancercelllines; CVCL_RA55
DR   GEO; GSM2069494
DR   GEO; GSM2069495
DR   GEO; GSM2069496
DR   GEO; GSM2069497
DR   Wikidata; Q54817050
RX   PubMed=27036029;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_68534; Enzalutamide (Xtandi; MDV-3100).
CC   Sequence variation: Mutation; HGNC; HGNC:644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4833 ! CWR-R1
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 12
//
RX   PubMed=27036029; DOI=10.18632/oncotarget.8456; PMCID=PMC5041979;
RA   Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H.,
RA   Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z.,
RA   Vander Griend D.J.;
RT   "Acquired resistance to the second-generation androgen receptor
RT   antagonist enzalutamide in castration-resistant prostate cancer.";
RL   Oncotarget 7:26259-26274(2016).
//